Company Overview and News
Monthly dividend stocks are popular with investors – and with good reason. Monthly payments line up better with monthly bills, particularly for retirees living off investment income. Over time, there’s even a modest incremental benefit from compounding, particularly for investors successfully using DRIP plans.
AMC XOM WSR EPR.PRG O.PRF O LTC OPRF FPI LANDP COP PBT FPI.PRB KR EPR LAND BPT GNL GNL.PRA
Ushering in good news for its shareholders, Realty Income Corporation (O - Free Report) recently announced its 97th dividend hike since the company’s NYSE listing in 1994. The company will now pay 22 cents per share compared with the 21.95 cents paid earlier. Realty Income will pay the dividend on Jul 13 to shareholders on record as of Jul 2, 2018. The latest dividend rate marks an annualized amount of $2.
KIM.PRI O.PRF O OPRF KIM.PRM KIM MAC KIM.PRL KIM.PRK KIM.PRJ
W.P. Carey (NYSE:WPC) acquired CPA-17, an unlisted real estate company managed by WPC. While we don't argue with the scale effects, the actual numbers suggest that this will have minimal positive impact on funds from operations (FFO). Let us show you the numbers.
O.PRF O WPC OPRF
Today, W.P. Carey announced that its board approved a merger pact in which CPA:17 will merge with a subsidiary of W.P. Carey in a stock-for-stock transaction valued at $6 billion.
STOR NNN.PRD NNN.PRF NNN.PRE PLD O.PRF O WPC OPRF NNN
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
Realty Income’s (O - Free Report) solid property acquisition volume is expected to keep the company on the growth curve. This freestanding retail real estate investment trust (REIT) derives majority of its retail rental revenues from tenants, belonging to service, non-discretionary and low-price retail businesses. Such businesses are less vulnerable to economic recessions as well as competition from Internet retailing.
PK LHO ABR O.PRF ENSG O OPRF ABRN ABRN.CL LHO.PRG LHO.PRJ ABR.PRB ABR.PRC LHO.PRI ABR.PRA LHO.PRH
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
Anyone paying even the least amount of attention to the tobacco industry is cognizant of the fact that Philip Morris (PM) is putting a full-court press on getting its IQOS smokeless product to surpass, supplant and replace tobacco products like cigarettes.
SOJA PM GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR NDAQ ROKU CLDT VZ WPC OHI
Investing in real assets such as Real Estate Securities, Infrastructure Securities, and Natural Resources Securities offers a route to have a consistent revenue stream. The downside is that most individual investors do not have the capital available to purchase a mortgage-backed security outright. Brookfield Real Assets Income Fund Inc. (RA) provides a perfect opportunity to get into this asset class.
ETP.PRC HTR.RT ETP HTR O.PRF BOI O OPRF HHY EPD RA
When sanity and reality returns, investors will flock back into the likes of Boeing, Raytheon and Lockheed Martin for safety, capital appreciation and income.
SOJA LMT GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24; Challengers have 5-9. WallStars show >.7% price-target upsides.
ABR PM HMLP O.PRF O OPRF KMB NNN.PRD ABRN NNN.PRF NNN.PRE ABRN.CL SIR SUN ABR.PRB HMLP.PRA ABR.PRC NNN ABR.PRA
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to O / Realty Income Corp. on message board site Silicon Investor.
as of ET